Time to Continuous Renal Replacement Therapy Initiation and 90-Day Major Adverse Kidney Events in Children and Young Adults
Importance: In clinical trials, the early or accelerated continuous renal replacement therapy (CRRT) initiation strategy among adults with acute kidney injury or volume overload has not demonstrated a survival benefit. Whether the timing of initiation of CRRT is associated with outcomes among children and young adults is unknown.
Objective: To determine whether timing of CRRT initiation, with and without consideration of volume overload (VO; <10% vs ≥10%), is associated with major adverse kidney events at 90 days (MAKE-90).
Design, Setting, and Participants: This multinational retrospective cohort study was conducted using data from the Worldwide Exploration of Renal Replacement Outcome Collaborative in Kidney Disease (WE-ROCK) registry from 2015 to 2021. Participants included children and young adults (birth to 25 years) receiving CRRT for acute kidney injury or VO at 32 centers across 7 countries. Statistical analysis was performed from February to July 2023.
Exposure: The primary exposure was time to CRRT initiation from intensive care unit admission.
Main Outcomes and measures: The primary outcome was MAKE-90 (death, dialysis dependence, or persistent kidney dysfunction [>25% decline in estimated glomerular filtration rate from baseline]).
Results: Data from 996 patients were entered into the registry. After exclusions (n = 27), 969 patients (440 [45.4%] female; 16 (1.9%) American Indian or Alaska Native, 40 (4.7%) Asian or Pacific Islander, 127 (14.9%) Black, 652 (76.4%) White, 18 (2.1%) more than 1 race; median [IQR] patient age, 8.8 [1.7-15.0] years) with data for the primary outcome (MAKE-90) were included. Median (IQR) time to CRRT initiation was 2 (1-6) days. MAKE-90 occurred in 630 patients (65.0%), of which 368 (58.4%) died. Among the 601 patients who survived, 262 (43.6%) had persistent kidney dysfunction. Of patients with persistent dysfunction, 91 (34.7%) were dependent on dialysis. Time to CRRT initiation was approximately 1 day longer among those with MAKE-90 (median [IQR], 3 [1-8] days vs 2 [1-4] days; P = .002). In the generalized propensity score-weighted regression, there were approximately 3% higher odds of MAKE-90 for each 1-day delay in CRRT initiation (odds ratio, 1.03 [95% CI, 1.02-1.04]).
Conclusions and Relevance: In this cohort study of children and young adults receiving CRRT, longer time to CRRT initiation was associated with greater risk of MAKE-90 outcomes, in particular, mortality. These findings suggest that prospective multicenter studies are needed to further delineate the appropriate time to initiate CRRT and the interaction between CRRT initiation timing and VO to continue to improve survival and reduce morbidity in this population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
JAMA network open - 7(2024), 1 vom: 02. Jan., Seite e2349871 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gist, Katja M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 09.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamanetworkopen.2023.49871 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366563130 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366563130 | ||
| 003 | DE-627 | ||
| 005 | 20240409232319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamanetworkopen.2023.49871 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM366563130 | ||
| 035 | |a (NLM)38165673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gist, Katja M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Time to Continuous Renal Replacement Therapy Initiation and 90-Day Major Adverse Kidney Events in Children and Young Adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: In clinical trials, the early or accelerated continuous renal replacement therapy (CRRT) initiation strategy among adults with acute kidney injury or volume overload has not demonstrated a survival benefit. Whether the timing of initiation of CRRT is associated with outcomes among children and young adults is unknown | ||
| 520 | |a Objective: To determine whether timing of CRRT initiation, with and without consideration of volume overload (VO; <10% vs ≥10%), is associated with major adverse kidney events at 90 days (MAKE-90) | ||
| 520 | |a Design, Setting, and Participants: This multinational retrospective cohort study was conducted using data from the Worldwide Exploration of Renal Replacement Outcome Collaborative in Kidney Disease (WE-ROCK) registry from 2015 to 2021. Participants included children and young adults (birth to 25 years) receiving CRRT for acute kidney injury or VO at 32 centers across 7 countries. Statistical analysis was performed from February to July 2023 | ||
| 520 | |a Exposure: The primary exposure was time to CRRT initiation from intensive care unit admission | ||
| 520 | |a Main Outcomes and measures: The primary outcome was MAKE-90 (death, dialysis dependence, or persistent kidney dysfunction [>25% decline in estimated glomerular filtration rate from baseline]) | ||
| 520 | |a Results: Data from 996 patients were entered into the registry. After exclusions (n = 27), 969 patients (440 [45.4%] female; 16 (1.9%) American Indian or Alaska Native, 40 (4.7%) Asian or Pacific Islander, 127 (14.9%) Black, 652 (76.4%) White, 18 (2.1%) more than 1 race; median [IQR] patient age, 8.8 [1.7-15.0] years) with data for the primary outcome (MAKE-90) were included. Median (IQR) time to CRRT initiation was 2 (1-6) days. MAKE-90 occurred in 630 patients (65.0%), of which 368 (58.4%) died. Among the 601 patients who survived, 262 (43.6%) had persistent kidney dysfunction. Of patients with persistent dysfunction, 91 (34.7%) were dependent on dialysis. Time to CRRT initiation was approximately 1 day longer among those with MAKE-90 (median [IQR], 3 [1-8] days vs 2 [1-4] days; P = .002). In the generalized propensity score-weighted regression, there were approximately 3% higher odds of MAKE-90 for each 1-day delay in CRRT initiation (odds ratio, 1.03 [95% CI, 1.02-1.04]) | ||
| 520 | |a Conclusions and Relevance: In this cohort study of children and young adults receiving CRRT, longer time to CRRT initiation was associated with greater risk of MAKE-90 outcomes, in particular, mortality. These findings suggest that prospective multicenter studies are needed to further delineate the appropriate time to initiate CRRT and the interaction between CRRT initiation timing and VO to continue to improve survival and reduce morbidity in this population | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Menon, Shina |e verfasserin |4 aut | |
| 700 | 1 | |a Anton-Martin, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Bigelow, Amee M |e verfasserin |4 aut | |
| 700 | 1 | |a Cortina, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Deep, Akash |e verfasserin |4 aut | |
| 700 | 1 | |a De la Mata-Navazo, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Gelbart, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Gorga, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Guzzo, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Mah, Kenneth E |e verfasserin |4 aut | |
| 700 | 1 | |a Ollberding, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, H Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Thadani, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Uber, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Zang, Huaiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zappitelli, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Selewski, David T |e verfasserin |4 aut | |
| 700 | 0 | |a WE-ROCK Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Ahern, Emily |e investigator |4 oth | |
| 700 | 1 | |a Akcan Arikan, Ayse |e investigator |4 oth | |
| 700 | 1 | |a Alhamoud, Issa |e investigator |4 oth | |
| 700 | 1 | |a Alobaidi, Rashid |e investigator |4 oth | |
| 700 | 1 | |a Balani, Shanthi S |e investigator |4 oth | |
| 700 | 1 | |a Barhight, Matthew |e investigator |4 oth | |
| 700 | 1 | |a Basalely, Abby |e investigator |4 oth | |
| 700 | 1 | |a Bottari, Gabriella |e investigator |4 oth | |
| 700 | 1 | |a Cappoli, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Ciccia, Eileen A |e investigator |4 oth | |
| 700 | 1 | |a Collins, Michaela |e investigator |4 oth | |
| 700 | 1 | |a Colosimo, Denise |e investigator |4 oth | |
| 700 | 1 | |a Damian, Mihaela A |e investigator |4 oth | |
| 700 | 1 | |a DeAbreu, Gabrielle |e investigator |4 oth | |
| 700 | 1 | |a Ding, Kathy L |e investigator |4 oth | |
| 700 | 1 | |a Dolan, Kristin J |e investigator |4 oth | |
| 700 | 1 | |a Fernandez LaFever, Sarah N |e investigator |4 oth | |
| 700 | 1 | |a Fuhrman, Dana Y |e investigator |4 oth | |
| 700 | 1 | |a Guzzi, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Haga, Taiki |e investigator |4 oth | |
| 700 | 1 | |a Harvey, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Hasson, Denise C |e investigator |4 oth | |
| 700 | 1 | |a Hill-Horowitza, Taylor |e investigator |4 oth | |
| 700 | 1 | |a Inthavong, Haleigh |e investigator |4 oth | |
| 700 | 1 | |a Joseph, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Kaddourah, Ahmad |e investigator |4 oth | |
| 700 | 1 | |a Kakajiwala, Aadil |e investigator |4 oth | |
| 700 | 1 | |a Kessel, Aaron D |e investigator |4 oth | |
| 700 | 1 | |a Korn, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Krallman, Kelli A |e investigator |4 oth | |
| 700 | 1 | |a Kwiatkowski, David M |e investigator |4 oth | |
| 700 | 1 | |a Lee, Jasmine |e investigator |4 oth | |
| 700 | 1 | |a Lequier, Laurance |e investigator |4 oth | |
| 700 | 1 | |a Madani Kia, Tina |e investigator |4 oth | |
| 700 | 1 | |a Marinari, Eleonora |e investigator |4 oth | |
| 700 | 1 | |a Martin, Susan D |e investigator |4 oth | |
| 700 | 1 | |a Mohamed, Tahagod H |e investigator |4 oth | |
| 700 | 1 | |a Morgan, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Mottes, Theresa |e investigator |4 oth | |
| 700 | 1 | |a Muff-Luett, Melissa A |e investigator |4 oth | |
| 700 | 1 | |a Namachivayam, Siva |e investigator |4 oth | |
| 700 | 1 | |a Neumayr, Tara M |e investigator |4 oth | |
| 700 | 1 | |a Nhan, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a O'Rourke, Abigail |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Matthew G |e investigator |4 oth | |
| 700 | 1 | |a Qutob, Dua |e investigator |4 oth | |
| 700 | 1 | |a Raggi, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Reynaud, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Ricci, Zaccaria |e investigator |4 oth | |
| 700 | 1 | |a Rumlow, Zachary A |e investigator |4 oth | |
| 700 | 1 | |a Santiago Lozano, María J |e investigator |4 oth | |
| 700 | 1 | |a See, Emily |e investigator |4 oth | |
| 700 | 1 | |a Serpe, Carmela |e investigator |4 oth | |
| 700 | 1 | |a Serratore, Alyssa |e investigator |4 oth | |
| 700 | 1 | |a Shah, Ananya |e investigator |4 oth | |
| 700 | 1 | |a Shih, Weiwen V |e investigator |4 oth | |
| 700 | 1 | |a Slagle, Cara L |e investigator |4 oth | |
| 700 | 1 | |a Solomon, Sonia |e investigator |4 oth | |
| 700 | 1 | |a Soranno, Danielle E |e investigator |4 oth | |
| 700 | 1 | |a Srivastava, Rachana |e investigator |4 oth | |
| 700 | 1 | |a Stanski, Natalja L |e investigator |4 oth | |
| 700 | 1 | |a Starr, Michelle C |e investigator |4 oth | |
| 700 | 1 | |a Stenson, Erin K |e investigator |4 oth | |
| 700 | 1 | |a Strong, Amy E |e investigator |4 oth | |
| 700 | 1 | |a Taylor, Susan A |e investigator |4 oth | |
| 700 | 1 | |a Van Wyk, Brynna |e investigator |4 oth | |
| 700 | 1 | |a Webb, Tennille N |e investigator |4 oth | |
| 700 | 1 | |a Zangla, Emily E |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA network open |d 2018 |g 7(2024), 1 vom: 02. Jan., Seite e2349871 |w (DE-627)NLM289300517 |x 2574-3805 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:1 |g day:02 |g month:01 |g pages:e2349871 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamanetworkopen.2023.49871 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 1 |b 02 |c 01 |h e2349871 | ||